“NOXCOVID European study is continuing to proceed as planned, with the Company announcing the encouraging initial safety data review of the first two dosages (ASX announcement 5 November 2020). Cohorts 3 and 4 are now fully enrolled and the Company anticipates issuing the next data review in early January 2021. With the pandemic reaching new heights in Europe, other hospitals in other European countries are now preparing to join the NOXCOVID trial.”
Nice to have the recent silence broken on NOXCOVID the statement seems to have bullish sentiment given the expansion to other hospitals.
Ann: Federal Government Approved Future Overseas R&D Expenditure, page-2
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.005(4.76%) |
Mkt cap ! $32.14M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 11.5¢ | 11.0¢ | $18.94K | 171.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 66800 | 1 |
View Market Depth
| Last trade - 14.48pm 08/11/2024 (20 minute delay) ? |
| NOX (ASX) Chart |